Journal of the American Society of Hypertension
Volume 2, Issue 4 , Pages 239-266 , July 2008

Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome

  • Melvin R. Hayden, MD

      Affiliations

    • Departments of Internal Medicine, Endocrinology Diabetes and Metabolism, and Diabetes and Cardiovascular Disease Research Center, School of Medicine, University of Missouri-Columbia, Health Sciences Center, Columbia, Missouri, USA
    • Corresponding Author InformationCorresponding author: Melvin R. Hayden, MD, Department of Internal Medicine, Endocrinology, Diabetes and Metabolism, Diabetes and Cardiovascular Disease Research Group, University of Missouri-Columbia, Missouri Health Sciences Center, MA410, DC043.00, Columbia, Missouri 65212. Tel: 573-346-3019; fax: 573-346-0152.
    • ,
  • James R. Sowers, MD

      Affiliations

    • Departments of Internal Medicine, Endocrinology Diabetes and Metabolism, Pharmacology, and Physiology, and Diabetes and Cardiovascular Disease Research Center, University of Missouri-Columbia, Health Sciences Center, and VA Medical Center, Columbia, Missouri, USA

Received 12 September 2007 ,Revised 6 December 2007

References 

  1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003;289:2560–2572
  2. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end–stage renal disease in men. N Engl J Med. 1996;334:13–18
  3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12- year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444
  4. Hayden MR, Sowers JR. Hypertension in type 2 diabetes mellitus. Insulin. 2006;1:22–37
  5. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286:H1597–H1602
  6. Hayden MR, Tyagi SC. Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP. 2002;3:86–108
  7. Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc. 2006;81:796–806
  8. Aksnes TA, Kjeldsen SE, Mancia G. The effect of antihypertensive agents on new–onset diabetes mellitus: time to amend the guidelines?. Am J Cardiovasc Drugs. 2006;6:139–147
  9. Abdeen MB, Chowdhury NA, Hayden MR, Ibdah JA. Nonalcoholic steatohepatitis and the cardiometabolic syndrome. J Cardiometab Syndr. 2006;1:36–40
  10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  11. Whaley-Connell A, Sowers JR. Chronic kidney disease and the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2006;8:546–548
  12. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374–381
  13. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86:713–718
  14. Denker PS, Pollock VE. Fasting serum insulin levels in essential hypertension (A meta–analysis). Arch Intern Med. 1992;152:1649–1651
  15. Grunfeld B, Balzareti M, Romo M, Gimenez M, Gutman R. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension. 1994;23:I12–I15
  16. Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskoaho H, Vapaatalo H, et al. Endothelial dysfunction and salt–sensitive hypertension in spontaneously diabetic Goto–Kakizaki rats. Hypertension. 2001;37:433–439
  17. Standley PR, Rose KA, Sowers JR. Increased basal arterial smooth muscle glucose transport in the Zucker rat. Am J Hypertens. 1995;8:48–52
  18. Roche HM, Phillips C, Gibney MJ. The metabolic syndrome: the crossroads of diet and genetics. Proc Nutr Soc. 2005;64:371–377
  19. Groop L. Genetics of the metabolic syndrome. Br J Nutr. 2000;83(Suppl 1):S39–S48
  20. Dandona P, Aljada A, Dhindsa S, Garg R. Insulin as an anti–inflammatory and antiatherosclerotic hormone. Clin Cornerstone. 2003;(Suppl 4):S13–S20
  21. Blendea MC, Jacobs D, Stump CS, McFarlane SI, Ogrin C, Bahtyiar G, et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren–2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab. 2005;288:E353–E359
  22. Lavoie JL, Bianco RA, Sakai K, Keen HL, Ryan MJ, Sigmund CD. Transgenic mice for studies of the renin–angiotensin system in hypertension. Acta Physiol Scand. 2004;181:571–577
  23. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation. 1998;98:2453–2460
  24. DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes. 1983;32:35–45
  25. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin–converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003;91:30H–37H
  26. Strazzullo P, Galletti F. Impact of the renin–angiotensin system on lipid and carbohydrate metabolism. Curr Opin Nephrol Hypertens. 2004;13:325–332
  27. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, et al. Blockade of the renin–angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens. 2004;22:1977–1982
  28. Ailhaud G, Fukamizu A, Massiera F, Negrel R, Saint–Marc P, Teboul M. Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes Relat Metab Disord. 2000;24(Suppl 4):S33–S35
  29. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes. 2002;51:1699–1707
  30. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005;54:8–14
  31. Wu D-A, Bu X, Warden CH, Shen DDC, Jeng C-Y, Sheu WHH, et al. Quantitative trait locus mapping of human blood pressure to a genetic region at or near the lipoprotein lipase gene locus on chromosome 8p22. J Clin Invest. 1996;97:2111–2118
  32. Liu E, Kitajima S, Higaki Y, Morimoto M, Sun H, Watanabe T, et al. High lipoprotein lipase activity increases insulin sensitivity in transgenic rabbits. Metabolism. 2005;54:132–138
  33. Bey L, Areiqat E, Sano A, Hamilton MT. Reduced lipoprotein lipase activity in postural skeletal muscle during aging. J Appl Physiol. 2001;91:687–692
  34. Hamilton MT, Etienne J, McClure WC, Pavey BS, Holloway AK. Role of local contractile activity and muscle fiber type on LPL regulation during exercise. Am J Physiol Endocrinol Metab. 1998;275:E1016–E1022
  35. Bey L, Hamilton MT. Suppression of skeletal muscle lipoprotein lipase activity during physical inactivity: a molecular reason to maintain daily low–intensity activity. J Physiol. 2003;551:673–682
  36. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care. 2003;26:688–696
  37. Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002;40:679–686
  38. Hayden MR, Whaley–Connell A, Chowdhury N, Sowers JR. Role of angiotensin II in diabetic cardiovascular and renal disease. Curr Opin Endocrinol Diabetes Obes. 2006;13:135–140
  39. Hayden MR, Stump CS, Sowers JR. Introduction: organ involvement in the cardiometabolic syndrome. J Cardiometab Syndr. 2006;1:16–24
  40. Poitout V, Robertson RP. Mini-review: secondary β–cell failure in type 2 diabetes–a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143:339–342
  41. Leung PS, Carlsson PO. Tissue renin–angiotensin system: its expression, localization, regulation and potential role in the pancreas. J Mol Endocrinol. 2001;26:155–164
  42. Leung PS, Chappell MC. A local pancreatic renin–angiotensin system: endocrine and exocrine roles. Int J Biochem Cell Biol. 2003;35:838–846
  43. Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin–generating system and dose–dependent inhibition of glucose–stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia. 2004;47:240–248
  44. Carlsson PO. The renin–angiotensin system in the endocrine pancreas. JOP. 2001;2:26–32
  45. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 1998;41:127–133
  46. Fliser D, Schaefer F, Schmid D, Veldhuis JD, Ritz E. Angiotensin II affects basal, pulsatile, and glucose–stimulated insulin secretion in humans. Hypertension. 1997;30:1156–1161
  47. Zhao H-L, Lai FMM, Tong PC, Zhong D-R, Yang D, Tomlinson B, et al. Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes. Diabetes. 2003;52:2759–2766
  48. Hayden MR. Islet amyloid and fibrosis in the cardiometabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2007;2:70–75
  49. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin–angiotensin system in the ZDF rat. Diabetes. 2004;53:989–997
  50. Hayden MR, Karuparthi PR, Habibi J, Wasekar C, Lastra G, Manrique C, et al. Ultra-structural islet study of early fibrosis in the Ren2 rat model of hypertension (Emerging role of the islet pancreatic pericyte–stellate cell). JOP. 2007;8:725–738
  51. Hayden MR, Karuparthi PR, Manrique CM, Lastra G, Habibi J, Sowers JR. Longitudinal ultrastructure study of islet amyloid in the HIP rat model of type 2 diabetes mellitus. Exp Biol Med (Maywood). 2007;232:772–779
  52. Hayden MR, Sowers JR. Redox imbalance in diabetes. Antioxid Redox Signal. 2007;9:865–867
  53. Hayden MR, Sowers JR. Isletopathy in type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress. Antioxid Redox Signal. 2007;9:891–910
  54. Hayden MR, Tyagi SC. “A” is for amylin and amyloid in type 2 diabetes mellitus. JOP. 2001;2:124–139
  55. Hayden MR, Tyagi SC, Kerklo MM, Nicolls MR. Type 2 diabetes mellitus as a conformational disease. JOP. 2005;6:287–302
  56. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM. Purification and characterization of a peptide from amyloid–rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A. 1987;84:8628–8632
  57. Reda TK, Geliebter A, Pi-Sunyer FX. Amylin, food intake, and obesity. Obes Res. 2002;10:1087–1091
  58. Lutz TA, Althaus J, Rossi R, Scharrer E. Anorectic effect of amylin is not transmitted by capsaicin–sensitive nerve fibers. Am J Physiol Regul Integr Comp Physiol. 1998;274:R1777–R1782
  59. Wookey PJ, Tikellis C, Du H-C, Qin H-F, Sexton PM, Cooper ME. Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin. Am J Physiol Renal Physiol. 1996;270:F289–F294
  60. Cooper ME, McNally PG, Phillips PA, Johnston CI. Amylin stimulates plasma renin concentration in humans. Hypertension. 1995;26:460–464
  61. Butler AE, Janson J, Soeller WC, Butler PC. Increased β-cell apoptosis prevents adaptive increase in β-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes. 2003;52:2304–2314
  62. Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, O'Connor DT. Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens. 2000;18:1611–1620
  63. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895–906
  64. Pepine CJ, Handberg EM, Cooper–DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease (The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial). JAMA. 2003;290:2805–2816
  65. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet. 1999;353:611–616
  66. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (The Heart Outcomes Prevention Evaluation Study Investigators). N Engl J Med. 2000;342:145–153
  67. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [Errata in: 2003;289:178; 2004;291:2196]. JAMA. 2002;288:2981–2997
  68. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif J-C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107:1291–1296
  69. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. PEACE Trial Investigators Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058–2068
  70. Thornley-Brown D, Wang X, Wright JT, Randall OS, Miller ER, Lash JP, et al. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Arch Intern Med. 2006;166:797–805
  71. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879–1886
  72. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766
  73. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation. 2005;112:48–53
  74. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE Study). J Hypertens. 2003;21:1563–1574
  75. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022–2031
  76. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, et al. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006;48:385–391
  77. Harper R, Ennis CN, Sheridan B, Atkinson AB, Johnston GD, Bell PM. Effects of low-dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ. 1994;309:226–230
  78. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care. 2006;29:1065–1070
  79. Mogensen CE. New concepts in blood pressure-lowering management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics. J Hum Hypertens. 2005;19:S15–S20
  80. Kjeldsen SE, Os I, Hoieggen A, Beckey K, Gleim GW, Oparil S. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs. 2005;5:17–22
  81. Mimran A, Weir MR. Angiotensin-receptor blockers and diuretics-advantages of combination. Blood Press. 2005;14:6–11
  82. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99:431–436
  83. Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, et al. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis. 2006;16:137–147
  84. Weber MA. Hypertension, the metabolic syndrome, and the risk of developing diabetes: is it time to change the guidelines?. J Clin Hypertens (Greenwich). 2004;6:425–427460
  85. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:e1–e8
  86. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201–207
  87. Perez-Stable E, Caralis PV. Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism. Am Heart J. 1983;106:245–251
  88. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203–209
  89. Fletcher A, Amery A, Birkenhager W, Bulpitt C, Clement D, De Leeuw P, et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertens. 1991;9:225–230
  90. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, et al. Influence of long–term, low–dose, diuretic–based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program (SHEP Cooperative Research Group). Arch Intern Med. 1998;158:741–751
  91. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963–969
  92. Samuelsson O, Hedner T, Berglund G, Persson B, Andersson OK, Wilhelmsen L. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non–selective beta–blockers and thiazide diuretics during 15 years treatment of middle–aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens. 1994;8:257–263
  93. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000;342:969–970
  94. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid–Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166:2191–2201
  95. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens. 2005;23:1777–1781
  96. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592–2597
  97. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care. 2004;27:247–255
  98. Gorden P, Sherman BM, Simopoulos AP. Glucose intolerance with hypokalemia: an increased proportion of circulating proinsulin-like component. J Clin Endocrinol Metab. 1972;34:235–240
  99. Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, Shocken D, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes. 1983;32:106–111
  100. Papadakis JA, Mikhailidis DP, Vrentzos GE, Kalikaki A, Kazakou I, Ganotakis ES. Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension. Clin Appl Thromb Hemost. 2005;11:139–146
  101. Skalska A, Gasowski J, Stepniewski M, Grodzicki T. Antioxidative protection in hypertensive patients treated with diuretics. Am J Hypertens. 2005;18:1130–1132
  102. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967–1975
  103. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ. 1989;298:1152–1157
  104. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press. 1992;1:92–101
  105. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus (Atherosclerosis Risk in Communities Study). N Engl J Med. 2000;342:905–912
  106. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents?. Am J Hypertens. 1998;11:1258–1265
  107. Wright AD, Barber SG, Kendall MJ, Poole PH. Beta-adrenoceptor-blocking drugs and blood sugar control in diabetes mellitus. BMJ. 1979;1:159–161
  108. Toda N. Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther. 2003;100:215–234
  109. Kuroedov A, Cosentino F, Lüscher TF. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev. 2004;22:155–168
  110. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and hemodynamics in hypertensive patients. J Hypertens. 2001;19:1429–1435
  111. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24:591–596
  112. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006;48:677–684
  113. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795–3801
  114. Gomes A, Costa D, Lima JL, Fernandes E. Antioxidant activity of β-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species?. Bioorg Med Chem. 2006;14:4568–4577
  115. Horani MH, Haas MJ, Mooradian AD. Suppression of hyperglycemia-induced superoxide formation and endothelin-1 gene expression by carvedilol. Am J Ther. 2006;13:2–7
  116. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005;23:589–596
  117. Koyama Y, Kodama K, Suzuki M, Harano Y. Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Am J Hypertens. 2002;15:927–931
  118. Yagi S, Goto S, Yamamoto T, Kurihara S, Katayama S. Effect of cilnidipine on insulin sensitivity in patients with essential hypertension. Hypertens Res. 2003;26:383–387
  119. McKeage K, Scott LJ. Manidipine: a review of its use in the management of hypertension. Drugs. 2004;64:1923–1940
  120. Lob H, Rosenkranz AC, Breitenbach T, Berkels R, Drummond G, Roesen R. Antioxidant and nitric oxide-sparing actions of dihydropyridines and ACE inhibitors differ in human endothelial cells. Pharmacology. 2006;76:8–18
  121. Rosenkranz AC, Lob H, Breitenbach T, Berkels R, Roesen R. Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors. Eur J Pharmacol. 2006;529:55–62
  122. Martinez MLL, Lopes LF, Coelho EB, Nobre F, Rocha JBT, Gerlach RF, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006;47:117–122
  123. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J. Benidipine, a long-acting calcium channel blocker, inhibits oxidative stress in polymorphonuclear cells in patients with essential hypertension. Hypertens Res. 2005;28:107–112
  124. Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907–913
  125. Zanella MT, Kohlmann O, Ribeiro AB. Treatment of obesity hypertension and diabetes syndrome. Hypertension. 2001;38:705–708
  126. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914–921
  127. Hobbs FR, Khan T, Collins B. Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension. Br J Gen Pract. 2005;55:437–443
  128. Andersson P-E, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men: relationship to changes in skeletal muscle blood flow. Am J Hypertens. 1996;9:323–333
  129. Bakris GL, Weir MR, Sowers JR. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med. 1996;101:33S–46S
  130. Dell'Omo G, Penno G, Pucci L, Pellegrini G, Scotti A, Del Prato S, et al. The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. Coron Artery Dis. 2005;16:67–73
  131. Lithell HO. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens. 1996;9:150S–154S
  132. Calo LA, Bertipaglia L, Pagnin E, Davis PA, Sartori M, Semplicini A, et al. Effect of doxazosin on oxidative stress related proteins in essential hypertensive patients. Clin Exp Hypertens. 2006;28:181–188
  133. Henriksen EJ, Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol. 2003;196:171–179
  134. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nature Rev Drug Disc. 2002;1:621–636
  135. Fisher NDL, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities?. J Am Soc Nephrol. 2005;16:592–599
  136. Rahuel J, Rasetti V, Maibaum J, Rüeger H, Göschke R, Cohen NC, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000;7:493–504
  137. Abuissa H, Jones PG, Marso SP, O'Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005;46:821–826
  138. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28:2261–2266
  139. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia. 2004;47:1519–1527
  140. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. DREAM Trial Investigators Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–1562
  141. Higashiura K, Ura N, Takada T, Li Y, Torii T, Togashi N, et al. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens. 2000;13:290–297
  142. Nawano M, Anai M, Funaki M, Kobayashi H, Kanda A, Fukushima Y, et al. Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism. 1999;48:1248–1255
  143. Ekelund U. Effects of angiotensin-converting enzyme inhibition on arterial, venous and capillary functions in cat skeletal muscle in vivo. Acta Physiol Scand. 1996;158:29–37
  144. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ. ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol Regul Integr Comp Physiol. 1999;277:R332–R336
  145. Feldman RD, Schmidt ND. Quinapril treatment enhances vascular sensitivity to insulin. J Hypertens. 2001;19:113–118
  146. Watanabe S, Tagawa T, Yamakawa K, Shimabukuro M, Ueda S. Inhibition of the renin–angiotensin system prevents free fatty acid–induced acute endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2005;25:2376–2380
  147. Steen MS, Foianini KR, Youngblood EB, Kinnick TR, Jacob S, Henriksen EJ. Interactions of exercise training and ACE inhibition on insulin action in obese Zucker rats. J Appl Physiol. 1999;86:2044–2051
  148. Bolterman RJ, Manriquez MC, Ortiz Ruiz MC, Juncos LA, Romero JC. Effects of captopril on the renin-angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats. Hypertension. 2005;46:943–947
  149. Yu W, Akishita M, Xi H, Nagai K, Sudoh N, Hasegawa H, et al. Angiotensin-converting enzyme inhibitor attenuates oxidative stress-induced endothelial cell apoptosis via p38 MAP kinase inhibition. Clin Chim Acta. 2006;364:328–334
  150. Huang Z, Jansson L, Sjöholm A. Pancreatic islet blood flow is selectively enhanced by captopril, irbesartan and pravastatin, and suppressed by palmitate. Biochem Biophys Res Commun. 2006;346:26–32
  151. Lupi R, Del Guerra S, Bugliani M, Boggi U, Mosca F, Torri S, et al. The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol. 2006;154:355–361
  152. Cheung BMY, Cheung GTY, Lauder IJ, Lau C-P, Kumana CR. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens. 2006;20:37–43
  153. Bergstrom G, Johansson I, Wickman A, Gan L, Thorup C. Brief losartan treatment in young spontaneously hypertensive rats abates long-term blood pressure elevation by effects on renal vascular structure. J Hypertens. 2002;20:1413–1421
  154. Olsen MH, Fossum E, Hoieggen A, Wachtell K, Hjerkinn E, Nesbitt SD, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE Substudy. J Hypertens. 2005;23:891–898
  155. Zandbergen AAM, Lamberts SWJ, Janssen JAMJL, Bootsma AH. Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I. Eur J Endocrinol. 2006;155:293–296
  156. Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism. 2006;55:1159–1164
  157. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-g activity. Circulation. 2004;109:2054–2057
  158. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, et al. Molecular characterization of new selective peroxisome proliferators-activated receptor-g modulators with angiotensin receptor blocking activity. Diabetes. 2005;54:3442–3452
  159. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 2004;43:993–1002
  160. Nagel JM, Tietz AB, Goke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin–resistant subjects. Metabolism. 2006;55:1149–1154
  161. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, et al. PPARγ-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005;46:137–143
  162. Okada K, Hirano T, Ran J, Adachi M. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res. 2004;27:293–299
  163. Shiuchi T, Iwai M, Li H-S, Wu L, Min L-J, Li J-M, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension. 2004;43:1003–1010
  164. Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt–induced hypertension. Am J Hypertens. 2005;18:1496–1502
  165. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol. 2002;89:18–25
  166. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52–61
  167. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–781
  168. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (Randomized Aldactone Evaluation Study Investigators). N Engl J Med. 1999;341:709–717
  169. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  170. Soberman JE, Weber KT. Spironolactone in congestive heart failure. Curr Hypertens Rep. 2000;2:451–456
  171. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004;217:53–58
  172. Epstein M, Calhoun DA. The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy. Curr Hypertens Rep. 2007;9:98–105
  173. Weinberger MH, White WB, Ruilope L-M, MacDonald TM, Davidson RC, Roniker B, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J. 2005;150:426–433
  174. Fallo F, Federspil G, Veglio F, Mulatero P. The metabolic syndrome in primary aldosteronism. Curr Hypertens Rep. 2007;9:106–111
  175. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91:454–459
  176. Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology. 2007;148:3773–3780
  177. Stanton A. Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2003;4:6–10
  178. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217–226
  179. Oh B-H, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157–1163
  180. Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens. 2007;21:780–787
  181. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42:1137–1143
  182. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012–1018
  183. Drummond W, Munger MA, Essop MR, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens. 2007;9:742–750
  184. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension. 2007;49:1047–1055
  185. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet. 2007;370:221–229
  186. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190–198
  187. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen N-C, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698–705
  188. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens. 2005;23:417–426
  189. Fogari R, Zoppi A, Preti P, Fogari E, Malamani G, Mugellini A. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens. 2001;14:921–926
  190. Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl. 1993;11:S49–S52
  191. Fisher NDL, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, et al. Responses to converting enzyme and renin inhibition: role of angiotensin II in humans. Hypertension. 1994;23:44–51
  192. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673–1679
  193. Hayden MR, Tyagi SC. Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction (Case report and systematic scientific review). Cardiovasc Diabet. 2005;4:1
  194. Burke LE, Dunbar-Jacob JM, Hill MN. Compliance with cardiovascular disease prevention strategies: a review of the research. Ann Behav Med. 1997;19:239–263

 This research was supported by NIH (RO1 HL73101-01A1), an investigator-initiated grant from Novartis Pharmaceuticals Corp., and the Veterans Affairs Merit System (0018) for Dr. Sowers.

PII: S1933-1711(07)00252-5

doi: 10.1016/j.jash.2007.12.002

Journal of the American Society of Hypertension
Volume 2, Issue 4 , Pages 239-266 , July 2008

Article Tools

* Image Usage & Resolution